| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2017: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Outline of Final Research Achievements |
To develop methods to select insulin secretagogue for individual patients and decide its administration protocol, I focused on individual differences and drug resistance concerning the efficacy of insulin secretagogue, and investigated the factors of individual differences of drug efficacy and establishment of drug resistance.As a factor of drug resistance, apoptosis of pancreatic β cells due to intracellular accumulation of LDL have been reported by some studies.
In this study, the influence of insulin secretagogue on the kinetics of low density lipoprotein (LDL) and proprotein convertase subtilisin/kexin type 9 (PCSK9) was analyzed, and PCSK9 secretion was fond to increase under certain conditions with some insulin secretagogue. On the other hand, it was also confirmed that the influence was vanishingly small under clinical conditions.
|
